Actualités
adMare

Flosonics Medical Secures $20 Million USD in Series C Funding Led by New Leaf Venture Partners to Accelerate Growth

*Cet article est disponible en anglais uniquement

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

*Cet article est disponible en anglais uniquement

Find Therapeutics annonce la nomination du Dr Anthony Johnson à son conseil d'administration

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

*Cet article est disponible en anglais uniquement

Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

*Cet article est disponible en anglais uniquement

– ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes –

– ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies –

Thérapeutiques Thryv annonce les résultats positifs de l'étude de preuve de concept WAVE 1 sur le syndrome du QT long.

Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.

Novo Nordisk entend acquérir Inversago Pharma afin de mettre au point de nouveaux traitements pour les personnes atteintes d’obésité, de diabète et d’autres maladies métaboliques

Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.

Le succès d'Abdera : le modèle adMare de création d'entreprise